This release about a new approach to the treatment of multiple myeloma is in many ways a model for other organizations reporting on similar studies.
This story provided a rosier picture of the benefit than was warranted. The appropriate overall survival statistic to report would have been the median survival rate in the entire population, not the average survival.
Inclusion of potential harms and more expert context elevate this story above the competing USA Today version.
Not a bad effort — but not quite as thorough as a competing NPR story on the same study.